WEST BRIDGEWATER, Mass., Oct. 17 /PRNewswire-FirstCall/ -- Pressure BioSciences, Inc. (Nasdaq: PBIO) ("PBI") today announced that a study focused on the discovery and identification of potential biomarkers of colon cancer that used pressure cycling technology (PCT) for the extraction of proteins from colon cancer tissues was presented on Sunday, October 14, 2007 at the Annual Scientific Meeting of the American College of Gastroenterology (ACG). The data were generated by scientists at the Brooklyn Hospital Center and the New York University (NYU) School of Medicine. The poster presentation was made by Dr. M. Momeni, MD of the Department of Gastroenterology of the Brooklyn Hospital Center.
Colon cancer is the second leading cause of cancer death in the United States. The probability of cure is directly related to the stage of the cancer at diagnosis and surgical resection. Identifying patients with this disease who have been shown to benefit from therapy is difficult at the present time due to the lack of reliable biomarkers. The purpose of this study was to identify proteins in tissue samples from patients with colon cancer that might be reliable biomarkers for this disease. To this end, pressure cycling technology (PCT) was used to extract the proteins from the various tissue samples that were studied.
Dr. Alexander Lazarev, Vice President of Research and Development of Pressure BioSciences, said: "The data presented by Dr. Momeni and her colleagues indicate that an apparent tumor signature protein (hCG1787564) extracted from colon tumor tissue by PCT might be a biomarker that could be of benefit to surgeons treating colon cancer patients. It is gratifying that PCT is beginning to be used by independent scientists in the preparation of their samples for important scientific studies, such as in the case of colon cancer research."
About Pressure BioSciences, Inc.
Pressure BioSciences, Inc. (PBI) is a publicly traded company focused on the development of a novel, enabling technology called Pressure Cycling Technology (PCT). PCT uses cycles of hydrostatic pressure between ambient and ultra-high levels (up to 35,000 psi and greater) to control bio-molecular interactions. PBI currently holds 13 US and 6 foreign patents covering multiple applications of PCT in the life sciences field, including such areas as genomic and proteomic sample preparation, pathogen inactivation, the control of enzymes, immunodiagnostics, and protein purification.
Forward Looking Statements
Statements contained in this press release regarding the Company's intentions, hopes, beliefs, expectations, or predictions of the future are "forward-looking'' statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include the use of the PCT SPS by the Brooklyn Hospital Center and the NYU School of Medicine, the results of their studies having been presented at the Annual Scientific Meeting of the American College of Gastroenterology. These statements are based upon the Company's current expectations, forecasts, and assumptions that are subject to risks, uncertainties, and other factors that could cause actual outcomes and results to differ materially from those indicated by these forward-looking statements. These risks, uncertainties, and other factors include, but are not limited to: unforeseen technological difficulties that the Company may encounter in the development of the PCT technology and the PCT Sample Preparation System; the possibility that other laboratories may be unable to duplicate the results generated by Dr. Momeni and her colleagues; the possibility that the data generated may not be beneficial in the development of new therapeutics and diagnostics for colon cancer; that due to competitive products, services, and technological advances, PCT may not be the preferred method of sample preparation by other scientists and laboratories; and the other risks and uncertainties discussed under the heading "Risk Factors" in the Company's Annual Report on Form 10-KSB for the year ended December 31, 2006, and other reports filed by the Company from time to time with the SEC. The Company undertakes no obligation to update any of the information included in this release, except as otherwise required by law.
Visit us at our website http://www.pressurebiosciences.com
|SOURCE Pressure BioSciences, Inc.|
Copyright©2007 PR Newswire.
All rights reserved